MAPT and Parkinson disease: While there is strong evidence reinforcing the use of concentrations of CSF Tau as a biomarker for PD, with Tau tangles appearing in 50% of patients, in addition to being a predictor for mild cognitive impairment (MCI), there is little evidence indicating its use in predicting future cases of cognitive impairment in PD.